What this result actually means
Grade Group 1 and Grade Group 2 differ mainly by the presence of Gleason pattern 4 in Grade Group 2. That can change surveillance versus treatment discussions.
The shift from Group 1 to Group 2 can materially change risk even when PSA is similar.
What changes the next decision
| What changes the next decision | What this result actually means |
|---|---|
| review tumor volume | The shift from Group 1 to Group 2 can materially change risk even when PSA is similar. |
| review MRI and stage | The shift from Group 1 to Group 2 can materially change risk even when PSA is similar. |
| consider genomic testing selectively | The shift from Group 1 to Group 2 can materially change risk even when PSA is similar. |
| discuss surveillance eligibility | The shift from Group 1 to Group 2 can materially change risk even when PSA is similar. |
What usually gets discussed next
The shift from Group 1 to Group 2 can materially change risk even when PSA is similar.
Grade Group 1 and Grade Group 2 differ mainly by the presence of Gleason pattern 4 in Grade Group 2. That can change surveillance versus treatment discussions.
What it cannot tell you
A prostate-wellness supplement does not replace MRI, biopsy, pathology diagnosis, BPH treatment or prostate-cancer treatment.
The shift from Group 1 to Group 2 can materially change risk even when PSA is similar.
Where a supplement fits
A prostate-wellness supplement does not replace MRI, biopsy, pathology diagnosis, BPH treatment or prostate-cancer treatment.
Review current Vigamaxx product information
A prostate-wellness supplement does not replace MRI, biopsy, pathology diagnosis, BPH treatment or prostate-cancer treatment.
vigamaxx.comFrequently asked questions
Does this result diagnose prostate cancer by itself?
No. MRI, PSA, DRE and most biopsy-risk markers must be interpreted in context. Tissue pathology is what establishes a prostate-cancer diagnosis.
Can a negative MRI rule out clinically significant cancer?
No. It lowers risk but does not reduce it to zero.
Why does PSA density matter with MRI?
PSA density adds prostate-volume context and can refine risk when MRI is negative or indeterminate.
Can a negative biopsy miss cancer?
Yes. Sampling error is possible, which is why persistent MRI or PSA concern can justify review or repeat biopsy.
What is the difference between targeted and systematic biopsy?
Targeted biopsy samples MRI-visible lesions; systematic biopsy samples predefined regions across the gland.
Does biopsy route matter?
Yes. Transperineal and transrectal routes differ in infection risk, anesthesia and access characteristics.
Should I stop blood thinners before biopsy?
Do not stop prescription blood thinners on your own. The biopsy team and prescribing clinician should coordinate any changes.
Are antibiotics always needed for prostate biopsy?
The plan depends on biopsy route, local protocol and patient risk. Follow the biopsy center's instructions.
What should I ask when MRI and biopsy disagree?
Ask whether the target was sampled, whether MRI or pathology should be re-reviewed and whether repeat targeted sampling is justified.
Can a supplement change PI-RADS or biopsy pathology?
No supplement should be presented as a way to reverse an MRI category or pathology diagnosis.
When is repeat biopsy considered?
When residual risk remains meaningful because of PSA behavior, MRI evolution, pathology uncertainty or concern about prior sampling quality.
What records should I bring to a second opinion?
Bring MRI images and report, pathology report and slides if available, PSA history, prostate volume, prior biopsy map and medication list.
Primary medical references
Last updated: 2026-09-02